Du är här

The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer

Författare:
  • Donal Brennan
  • Sara Ek (Assistant Professor)
  • Emma Doyle
  • Thomas Drew
  • Michael Foley
  • Grainne Flannelly
  • Darren P O´Conner
  • William M Gallagher
  • Sami Kilpinen
  • Olli-Pekka Kallioniemi
  • Karin Jirström
  • Colm O'Herlihy
  • Carl Borrebaeck
Publiceringsår: 2009
Språk: Engelska
Sidor: 1510-1517
Publikation/Tidskrift/Serie: European Journal of Cancer
Volym: 45
Nummer: 8
Dokumenttyp: Artikel
Förlag: Elsevier Science Ltd

Sammanfattning

Abstract
Background:
Current prognostic molecular markers for epithelial ovarian cancer (EOC) are
insufficient. The aim of the current study was to investigate the role of Sox11 in EOC
Methods:
Using an in silico transcriptomic screen Sox11 was identified as a potential EOC
biomarker. Sox11 protein expression was evaluated using immunohistochemistry (IHC)
in 76 EOC cases, which were analyzed using automated algorithms to develop a
quantitative scoring model.
Results:
Sox11 mRNA expression was up-regulated in EOC compared to normal tissues.
Automated analysis of Sox11 in the EOC cohort revealed high expression of Sox11, in
40% of tumours, who had an improved recurrence free survival (RFS) (p= 0.002).
Multivariate analysis confirmed Sox11 was an independent predictor of improved RFS
after controlling for stage and grade.
Conclusions:
These data suggest that Sox11 is a new prognostic marker in EOC. Loss of SOX 11 is
associated with a decreased RFS and a more aggressive phenotype.

Disputation

Nyckelord

  • Medicine and Health Sciences

Övriga

Published
Yes
  • ISSN: 0959-8049

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

LERU logotype U21 logotype

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen